Dexmedetomidine: dexmedetomidine infusion rule in prevention of IRI
Normal Saline: normal saline infusion as a placebo
Study summary
the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability
Eligibility
Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
1. Patients aged 18-60 years.
2. Model for end-stage liver disease (MELD) score 12-20.
3. No severe hemodynamic instability.
4. The liver donors aged 18-50 years and the sum of macro- and microvesicular hepatic steatosis has to be less than 30%.
Exclusion Criteria:
1. History of psychiatric/neurological illness.
2. Cardiovascular disease.
3. Hypertensive patients.
4. Morbid obese patients (body mass index (BMI) \> 35).
5. Chronic obstructive pulmonary disease; pulmonary dysfunction (PaO2 less than 60 mmHg).
6. Known allergic reaction to any of the study medications.
Primary outcome measure(s)
syndecan-1 level — 48 hours Change in syndecan-1 level 5 minutes after hepatic artery declamping
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
